About +
Our Story
Meet the Team
Inhaled Interferon β +
Our Programmes
Publications
Investors +
Share Price Information
Reports & Presentations
Investor News
Shareholder Information
AIM Rule 26
Corporate Governance
News +
Press Releases & Media
TR-1/Options Press Releases
Careers
Contact
About
Inhaled Interferon β
Investors
News
Careers
Contact
Back
Our Story
Meet the Team
Back
Our Programmes
Publications
Back
Share Price Information
Reports & Presentations
Investor News
Shareholder Information
AIM Rule 26
Corporate Governance
Back
Press Releases & Media
TR-1/Options Press Releases
← Back to Media
In the News
WebMD's John Whyte MD talks to Synairgen CEO Richard Marsden
Synairgen founder Professor Sir Stephen Holgate talks to John Whyte MD of WebMD
Synairgen presents data on antiviral activity of lead asset
Synairgen 'delighted' to get green light for US government-sponsored Phase III trials, starting soon
Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants
